Inductive Bio launches Beacon-2 to predict human drug doses
Sep 17, 2026
Biotech
Inductive Bio Secures $25M to Advance AI in Drug Discovery
May 7, 2025
Inductive Bio has raised $25 million in Series A funding to enhance its AI platform for small molecule drug discovery, announced in a press release. The funding round was led by Obvious Ventures with participation from Andreessen Horowitz and Lux Capital.
Inductive Bio has raised $25 million in Series A funding to advance its AI-driven platform for small molecule drug discovery, announced in a press release. The funding round was led by Obvious Ventures, with participation from Andreessen Horowitz (a16z), Lux Capital, and other investors.
Inductive Bio's approach involves a pre-competitive data consortium where multiple companies contribute anonymized data, creating a foundational dataset for AI models to learn from real-world drug discovery programs. This data powers Inductive's Compass platform, which predicts a drug's ADMET properties before synthesis, aiding chemists in designing molecules with higher success potential.
The company plans to use the new funding to expand its AI model research and development, grow its data consortium, and deploy its technology across the industry. Inductive Bio aims to democratize AI tools in drug discovery, leveling the playing field for both startups and large pharmaceutical companies.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Funding
Oct 16 Intuit Agrees to Acquire AI Billing Startup Sequence for Reported $200 Million Oct 16 Matters Raises $5 Million to Build AI Consumer Bank Oct 16 KP Labs raises €4.42 million for AI data processing in orbit Oct 15 Origin Raises $20 Million for Autonomous Construction Robots Oct 15 Symbe Raises $5.7 Million for AI Sales PlatformMore from Life Sciences
Oct 16 Study Tests Smartphone AI for Children's Lung Sounds Oct 16 Manhattan Physician Invests in RunPractice Oct 16 Attilio appoints Buck Institute CEO Eric Verdin as cochairman Oct 16 Aignostics launches HETA Clinical for pathology workflows Oct 16 Specialty1 Partners Invests in AI for Dental Practice OperationsFree newsletter
Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
The Hackett Group
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Illumina Launches BioInsight Platform for Genomic Research
Oct 14, 2026
Biotech
Enveda Raises $311 Million for AI Drug Discovery
Sep 24, 2026
Funding
Basecamp Research Raises $140 Million for AI Designed Therapeutics
Sep 24, 2026
Funding
INmune Bio and QCi Apply Quantum Computing to XPro Research
Oct 14, 2026
Life Sciences
Apex Intelligence Raises Nearly $50 Million for Self Improving AI Models
Sep 16, 2026
Funding
Free, six days a week
Daily AI Brief: the AI news that matters, in your inbox.